Table 5.

Survival analysis in the R ^{3 to <6 months}/T group, according to clinicopathological features. Abbreviations: OS, overall survival; mOS, median overall survival; PFS, progression-free survival; mPFS, median progression-free survival; 95% CI, 95% confidence interval; HR, hazard ratio; T, trifluridine/tipiracil; R, regorafenib; MSI, microsatellite instability.

Variables	OS				PFS
	mOS (Months)	95% CI	HR (95% CI)	p-Value	mPFS (Months)	95% CI	HR (95% CI)	p-Value
Age				0.2877				0.4812
<70 years	14.3	12.8–54.3	0.70		11.3	8.8–39.4	0.80
≥70 years	12.9	12.1–39.5	(0.37–1.33)		10.2	8.4–28.4	(0.45–1.45)
Sex				0.8292				0.1731
Female	12.9	8.8–51.6	0.92		9.7	7.3–32.7	0.60
Male	13.7	12.3–54.3	(0.47–1.80)		11.7	9.4–39.4	(0.29–1.24)
RAS status				0.7623				0.9596
Wild type	17.6	10.8–39.5	0.90		11.5	7.3–32.7	0.98
Mutant type	13.9	12.3–54.3	(0.48–1.69)		10.2	8.8–39.4	(0.54–1.78)
Primary tumor location				0.6560				0.8442
Right side	13.1	8.3–17.6	0.85		10.1	6.8–34.9	0.94
Left side	13.7	12.6–54.3	(0.44–1.67)		11.0	9.4–39.4	(0.51–1.72)
MSI				0.5998				0.9499
yes	13.1	13.1–13.1	2.0		12.4	12.4–12.4	0.93
no	13.9	12.3–54.3	(0.14–26.9)		11.0	9.4–39.4	(0.13–6.70)
ECOG PS			0.44 (0.20–0.98)	0.0439			0.67 (0.38–1.17)	0.0251
0	28.4	8.4–32.7			13.3	8.8–34.9
1	13.3	8.8–20.7			10.0	7.8–39.4
2	10.2	9.2–39.4			8.4	6.5–32.7
Metastatic sites			0.88 (0.35–2.19)	0.8514			0.89 (0.38–2.06)	0.9690
Liver only	17.6	7.6–29.8			14.9	6.5–20.5
Liver + other	13.9	12.5–51.6			11.0	10.0–34.9
Others	12.8	11.4–54.3			9.6	8.3–39.4
Prior Lines of treatment				0.6937				0.6372
2 lines	13.7	12.5–54.3	0.85		11.0	9.4–39.4	0.84
3 lines	13.3	8.5–39.5	(0.39–1.85)		8.4	6.5–28.4	(0.42–1.68)